NeuroFront has partnered with Jingsai Corp. to exclusively distribute its FDA-approved device Relivion for treating migraines and depression in Taiwan.

Target Information

NeuroFront, a biotechnology company based in Shanghai, focuses on developing breakthrough therapies in the field of neuroscience. The company has entered the clinical stage of research for its innovative medical device, Relivion, designed to treat migraines and depression. Relivion has received clearance from the U.S. Food and Drug Administration (FDA) for migraine treatment and is currently undergoing late-stage clinical trials for depressive disorders.

Relivion is a lightweight, wearable device that stimulates the occipital nerve at the back of the head and the trigeminal nerve in the forehead. This neurostimulation releases neurotransmitters that positively affect pain and emotional regulation. The device is complemented by a mobile application, allowing patients to share home treatment data with their doctors, facilitating personalized treatment plans and identifying potential triggers for migraine attacks.

Industry Overview in Taiwan

The healthcare and biotechnology sectors in Taiwan have been rapidly evolving, with increasing investments in research and development. Taiwan's government actively promotes innovation in the medical technology field, providing f